Mylan sets date for Perrigo meeting; Teva's Allergan generics deal tops the charts in Israel;

@FiercePharma: $BMY CEO talks up immuno-oncology space, coming hep C competition in Japan. Article | Follow @FiercePharma

@EricPFierce: ICYMI: Lupin lands its first US manufacturing site with $880M deal for GAVIS, 6-year-old NJ firm. More | Follow @EricPFierce

@CarlyHFierce: About that brand/generics hybrid thing? Make that brands only, Allergan says with Teva deal. News | Follow @CarlyHFierce

> Mylan ($MYL) has picked Aug. 28 for a special shareholder meeting to determine whether to go ahead with its bid for Perrigo ($PRGO). Report

> In H1, Almirall's normalized net profit rose to €63.8 million from €19.1 million in the year-ago period. Report

> Teva's ($TEVA) Monday deal to buy Allergan's ($AGN) generics business for $40.5 billion dwarfed the other four top transactions in Israeli history by at least $30 billion, according to Bloomberg data. More

> GlaxoSmithKline's ($GSK) Nigerian unit reported a 66% drop in first-half profit. Report

Medical Device News

@FierceMedDev: Docs dole out recs for reducing fetal ultrasound procedures in the U.S. Story | Follow @FierceMedDev

@EmilyWFierce: #FDA launches probe into safety of common MRI contrast agent. Article | Follow @EmilyWFierce

> Cepheid readies for 2016 launch of point-of-care molecular Dx system for use anywhere. More

> Micro-cap Nephros secures up to $10M to back its alternative to hemodialysis. Story

Biotech News

@FierceBiotech: Cutting-edge research centers back Deerfield's $550M biotech venture fund. Story | Follow @FierceBiotech

@JohnCFierce: This just in, $SFY has decided to outsource all pipeline work and restrict R&D effort to writing checks. $REGN $ALNY | Follow @JohnCFierce

@DamianFierce: Marc Beer resignation PR includes a line about continuing "the company's commitment to high integrity and ethics." | Follow @DamianFierce

> Progenics' orphan cancer drug picks up the FDA's 'breakthrough' tag. Article

> Cutting-edge research centers back Deerfield's $550M biotech venture fund. More

> Esperion looks to disrupt the PCSK9 race with new cardio data. News

Drug Delivery News

> IPOs: EyeGate tries again following deal with Valeant, Parkinson's specialist to debut soon. More

> Alnylam launches trial of one of its RNAi candidates. Article

> Pill holds a ring-shaped device that could deliver drugs to the stomach long-term. Story

> ASU team offers precise DNA origami technique with novel shapes and delivery potential. More

> Ra Pharma gets $58.5M to challenge a rare disease's intravenous incumbent. Article

Pharma Manufacturing News

> Avista Pharma snaps up NC manufacturing facility from rival Scynexis. Report

> Teva expands recall of cancer drug Adrucil. Story

> Androxy returns to market after 9-month lapse. News

> EU ban on more than 700 drugs set for Aug. 21. Item

> Hospira recall of ketorolac now close to 40 million vials. Article

Pharma Asia News

> Fallout from India's GVK means $1B lost in drug exports by March 2016. News

> Trans-Pacific Partnership impasse on data exclusivity for biologics softens. Story

> Roche COO O'Day highlights emerging markets trends on Q2 call. More

> Eli Lilly execs on Q2 call discuss Japan opportunities, China slowdown. Article

> EU-wide ban starts Aug. 21 on 700-plus drugs tested by India's GVK Bio Sciences. Report

And Finally... Gadolinium-enhancing contrast agents used in MRI imaging may build up in the brain after repeated scans, the FDA warns. More

Suggested Articles

Belén Garijo, currently CEO of Merck Healthcare, will succeed Stefan Oschmann as the German company's chief exec when his tenure ends in April 2021.

More than 60 researchers and bioethicists called on Pfizer to take time to collect more COVID-19 vaccine safety data, Bloomberg reports. 

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.